Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19
Our data suggest that dexamethasone protects against COVID-19 endothelium-induced coagulopathy. These findings are in line with the decreased prevalence of venous thrombosis among hospitalized patients with COVID-19 treated with dexamethasone.
Authors
- Romy Younan (ORCID: https://orcid.org/0000-0003-4447-0146)
- Olivier Sanchez (ORCID: https://orcid.org/0000-0003-1633-8391)
- David M. Smadja (ORCID: https://orcid.org/0000-0001-7731-9202)
- Xavier Loyer (ORCID: https://orcid.org/0000-0003-4294-3608)
- Bertrand Hermann (ORCID: https://orcid.org/0000-0001-9071-3415)
- Lina Khider (ORCID: https://orcid.org/0000-0002-7748-183X)
- Jean‐Luc Diehl (ORCID: https://orcid.org/0000-0001-5378-6762)
- Nicolas Gendron (ORCID: https://orcid.org/0000-0003-4852-4738)
- Paul Billoir (ORCID: https://orcid.org/0000-0001-5632-7713)
- Chantal M. Boulanger (ORCID: https://orcid.org/0000-0002-3687-651X)
- Gilles Châtellier (ORCID: https://orcid.org/0000-0002-6373-8956)
- Aurélien Philippe (ORCID: https://orcid.org/0000-0003-3644-7464)
- Jeanne Rancic
- Nicolas Péron
- Caroline Hauw-Berlemont
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Normandie Université (FR)
- Hôpital Européen (FR)
- Paris Cardiovascular Research Center (FR)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- Arteriosclerosis Thrombosis and Vascular Biology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1161/atvbaha.125.322774
- Citations
- 3
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.19